Effective Viral Vector SARS ‐CoV‐2 Booster Vaccination in a Patient with Rheumatoid Arthritis after Initial Ineffective mRNA Vaccine Response
AbstractManaging patients with rheumatic disease during the COVID-19 pandemic has posed a unique challenge. Immunosuppressed patients are at an increased risk for developing severe COVID-19 and may not derive full protection from the vaccine (1-5). Thus, it is paramount we develop strategies whereby rheumatic disease patients can be protected from the pandemic virus and its variants.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Matthew C. Baker,
Vamsee Mallajosyula,
Mark M. Davis,
Scott D. Boyd,
Kari C. Nadeau,
William H. Robinson Tags: LETTER TO THE EDITOR Source Type: research